Desuden konkluderede CHMP, at der er brug for flere oplysninger for bedre at få belyst den langsigtede sikkerhed af Protopic hvad angår sammenhængen med ondartede lidelser.
In addition, the CHMP concluded that further data are required to better elicit the long-term safety of Protopic in respect of its association with malignancies.